Sumitomo Mitsui DS Asset Management Company Ltd Has $16.88 Million Stock Holdings in Danaher Corporation $DHR

Key Points

• Sumitomo Mitsui DS Asset Management increased its stake in Danaher Corporation by 3.9% during Q2, holding 85,472 shares valued at $16.88 million after acquiring an additional 3,195 shares.
• Danaher reported $1.80 EPS for the last quarter, beating expectations of $1.64, with revenues of $5.94 billion, marking a 3.4% increase year-over-year.
• The firm's quarterly dividend stands at $0.32, resulting in an annualized yield of 0.7%, with record date set for September 26th.

Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Danaher Corporation (NYSE:DHR - Free Report) by 3.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 85,472 shares of the conglomerate's stock after purchasing an additional 3,195 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Danaher were worth $16,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. GHP Investment Advisors Inc. raised its position in shares of Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter worth about $27,000. Sierra Ocean LLC raised its position in shares of Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher during the 1st quarter worth about $31,000. Finally, Dunhill Financial LLC raised its position in shares of Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after acquiring an additional 67 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Performance

Shares of Danaher stock traded down $1.96 on Friday, reaching $193.31. 5,932,115 shares of the company were exchanged, compared to its average volume of 3,243,103. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company's 50-day moving average is $200.17 and its two-hundred day moving average is $198.30. The firm has a market cap of $138.42 billion, a price-to-earnings ratio of 41.13, a P/E/G ratio of 2.70 and a beta of 0.75. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's payout ratio is presently 27.23%.

Analyst Ratings Changes

A number of research analysts recently issued reports on DHR shares. Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim restated a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. UBS Group dropped their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Finally, Robert W. Baird raised their price target on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $246.35.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.